102 results
Page 4 of 6
8-K
EX-99.1
y6hsy t8bg
25 Nov 20
Equillium Provides Itolizumab COVID-19 Program Update
8:01am
8-K
EX-99.1
4nm9mq4z 3ueytlvjgd
10 Nov 20
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
4:11pm
8-K
EX-99.1
p01h0j0a03g4k4y0s
29 Oct 20
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
5:12pm
8-K
EX-99.2
su5xfmfvoy9fv8 pakgd
14 Aug 20
Equillium Announces Proposed Public Offering of Common Stock
4:50pm
8-K
EX-99.1
ym8clr9zb4gdcj3i3h
14 Aug 20
Equillium Announces Proposed Public Offering of Common Stock
4:50pm
424B5
sr918hhykm8tcy f9y
14 Aug 20
Prospectus supplement for primary offering
4:45pm
424B5
a7329xrawbh77y
13 Aug 20
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
52bh2gdnw18pf65fvkh3
12 Aug 20
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
8:40am
8-K
EX-99.1
mkhfaat
10 Aug 20
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
5:21pm
424B5
8xi89
14 Jul 20
Prospectus supplement for primary offering
6:05am
8-K
EX-99.1
1fkggb76 mkiou
13 Jul 20
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon
6:05am
8-K
EX-99.1
oik8 d9xuo18kt51fqcc
13 May 20
Equillium Reports First Quarter 2020 Financial Results
4:10pm
424B3
cb7gab9hnilvr86 anl
7 Apr 20
Prospectus supplement
4:57pm
8-K
EX-99.1
uh25 setr79yns1fvx9r
26 Mar 20
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
hq4wfi9 5yvrgb7bod3
12 Dec 19
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to
7:05am